Drug intelligence / Profile preview

GDC-0134

Development stage: Phase 1
Lead developer: Genentech
Modality: Small Molecules
Administration: Oral

Overview

GDC-0134 is a potent, selective, orally available, brain‐penetrant small-molecule inhibitor of dual leucine zipper kinase (DLK). DLK regulates the c-Jun N-terminal kinase (JNK) pathway involved in axon degeneration and neuronal apoptosis following injury. By inhibiting DLK, GDC-0134 aims to block JNK activation and protect neurons from degeneration. It was developed by Genentech for the treatment of amyotrophic lateral sclerosis (ALS), with the goal of slowing disease progression by preventing motor neuron loss[1][3][5].

Targets

MAP3K12 (Mitogen-activated protein kinase kinase kinase 12)

Beyond the preview

Go deeper on GDC-0134.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GDC-0134.

Explore the full profile